ETF Evaluator:
ARK Genomic Revolution ETF (ARKG)
Follow This ETF
(as of Jul 31)
Best Performing in Health Over the Last Year
| 177.8% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 114.6% | ALPS Medical Breakthroughs ETF (SBIO) |
| 91.7% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 83.9% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 79.5% | iShares Neuroscience and Healthcare ETF (IBRN) |
Risk
Index
Risk
Index
ETF Details
ARK Genomic Revolution ETF Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed Sector Equity Health exchange-traded fund (ETF). ARK ETF Trust launched the ETF in 2014.
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
About ARK Genomic Revolution ETF (ARKG)
There are 1 members of the management team with an average tenure of 11.67 years: Catherine Wood (2014). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and MSCI World NR USD index with a weighting of 100%. ARK Genomic Revolution ETF has 34 securities in its portfolio. The top 10 holdings constitute 60.3% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
ARK Genomic Revolution ETF is part of the Equity global asset class and is within the Sector Equity ETF group. ARK Genomic Revolution ETF has 9.3% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 90.6% There is 9.3% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). ARK Genomic Revolution ETF has 0.2% of the portfolio in cash.
Assets Under Management
The fund has $1 billion in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
ARKG Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The ARK Genomic Revolution ETF expense ratio is above average compared to funds in the Health category. ARK Genomic Revolution ETF has an expense ratio of 0.75%, which is 45% higher than its category average, making the fund expense ratio grade a F. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. ARK Genomic Revolution ETF has a portfolio turnover rate of 33%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 40% for the Health category.
Recently, in the month of June 2026, ARK Genomic Revolution ETF returned 21.6%, which earned it a grade of A, as the Health category had an average return of 8.7%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
ARK Genomic Revolution ETF has a trailing yield of 0.00%, which is below the 1.12% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
ARK Genomic Revolution ETF Grades
Year to date, the ETF has returned 45.4%, 35.3 percentage points better than the category, which translates into a grade of A. The fund has returned 73.0% over the past year (grade of A), 7.2% over the past three years (grade of D) and -14.5% per year over the past five years (grade of F) and 10.4% per year over the past 10 years (grade of B).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about ARK Genomic Revolution ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
ARKG Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| ARKG Return (NAV) | 21.6% | 59.1% | 73.0% | 7.2% | -14.5% | 10.4% |
| ARKG Return (Price) | 21.4% | 59.2% | 72.7% | 7.3% | -14.5% | 10.4% |
| NAV +/- Price Return | 0.142% | -0.140% | 0.294% | -0.006% | -0.003% | -0.026% |
| Health Avg | 8.7% | 13.9% | 37.6% | 10.6% | 1.5% | 9.5% |
| ARKG Grade (NAV) | A | A | A | D | F | B |
| +/- Category (NAV) | 12.9% | 45.1% | 35.4% | -3.4% | -16.0% | 0.9% |
| ARKG Tax-Cost Ratio | na | na | 0.0% | 0.0% | 0.0% | 0.3% |
ARKG Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| ARKG Return (NAV) | 45.4% | 22.7% | -28.1% | 16.2% | -53.9% | -33.9% | 180.5% | 43.7% | 0.6% | 45.4% | -18.4% |
| ARKG Return (Price) | 45.2% | 23.0% | -28.2% | 16.2% | -53.9% | -33.9% | 180.6% | 44.1% | -0.1% | 46.6% | -19.3% |
| NAV +/- Price Ret | -0.005% | 0.014% | 0.005% | 0.001% | -0.001% | 0.001% | 0.000% | 0.7% | -118.2% | 2.6% | 4.9% |
| Health Avg | 10.1% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| ARKG Grade (NAV) | A | C | F | A | F | F | A | A | B | A | D |
| +/- Category | 35.3% | 1.0% | -28.2% | 14.0% | -37.6% | -38.2% | 150.0% | 18.4% | 2.1% | 19.0% | -8.2% |
| Risk Measures | |
| Beta: | 2.38 |
| R-Squared: | 52% |
| Standard Deviation: | 41.8% |
| Category Risk Index: | 2.09 |
| Category Risk Rating: | High |
| Total Risk Index: | 3.44 |
| Total Risk Rating: | High |
| Portfolio Characteristics | |
| Yield: | 0.0% |
| Total Assets: | $ 1,730 Mil |
| Share Class Assets: | $ 1,730 Mil |
| Turnover: | 33.0% |
| Expense Ratio: | 0.75% |
| Index Fund: | No |
| Index Tracked: | S&P 500 (TR) (1970) |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 1 | |||
| Longest Tenure: 11.7 years | |||
| Average Tenure: 11.7 years | |||
| Managers (Year): Wood Catherine (2014) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 34 |
| % in Top 10 Holdings: | 60.3% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 9.3% |
Portfolio Allocation |
|
| Domestic Stock: | 90.6% |
| Foreign Stock: | 9.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.2% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | ARK ETF Trust |
| Phone Number: | 727-810-8160 |
| Website: | www.ark-funds.com |
| Inception Date: | October 31, 2014 |
Expenses and Fees
| Expense Ratio (%): | 0.75% (Rating: Above Avg) |
| Category Average Expense Ratio (%): | 0.52% |
